Q3 2024 Medicure Inc Earnings Call Transcript
Key Points
- Medicure Inc (MCUJF) reported a net income of $680,000 for Q3 2024, a significant improvement from a loss in the previous quarter.
- Revenue from Marley Drug increased to $2.7 million, up from $2.2 million in the prior year, indicating growth in the pharmacy business.
- ZYPITAMAG sales through the traditional insured channel increased due to greater utilization through insurance formularies, specifically Medicare Part D.
- Medicure Inc (MCUJF) remains debt-free, providing financial stability and flexibility for future investments.
- The company received Fast Track designation for MC-1, facilitating the review process for FDA approval, which could lead to significant market potential.
- Total revenue for Q3 2024 was $5.2 million, a decrease from $6 million in the same quarter of the previous year.
- AGGRASTAT revenue decreased due to pricing pressures from increased competition, specifically from generic tirofiban hydrochloride.
- Adjusted EBITDA for Q3 2024 was negative $467,000, down from a positive $429,000 in the same period of the previous year.
- Higher research and development expenses and general and administrative expenses contributed to the negative EBITDA.
- The company experienced a foreign exchange loss of $46,000 due to changes in the US dollar exchange rate.
Welcome to Medicure's earnings conference call for the quarter ended September 30, 2024. My name is Jenny and I will be your operator for today's call. (Operator Instructions)
Before we proceed, I would like to remind everyone that this presentation contains forward-looking statements relating to future results, events and expectations, which are made pursuant to the Safe Harbor provisions of the US Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and uncertainties, which could cause the company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, those described in the company's most recent annual information form and Form 20-F.
Later, we will conduct a question-and-answer session. Please note that this conference is being recorded, and today's date is November 26, 2024.
I would now like to turn the conference call over to Dr. Albert Friesen, Chief Executive Officer of Medicure Incorporated. Please go ahead, Dr. Friesen.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
